All treatments
Treatment
Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Randomized, Double-Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck
This study looks at new treatments for a type of head and neck cancer. It compares two drug combinations to see if they help shrink tumors and improve how long people live, while also checking for side effects.
For: Squamous cell carcinoma of the head and neck (SCCHN)Greece · France · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
This study is for people with a certain type of advanced lung cancer that hasn't been treated before. It tests a new drug, tiragolumab, combined with an existing drug, atezolizumab, to see if this combination works better than atezolizumab alone. The aim is to find ways to help people live longer and with better quality of life.
For: Non-small cell lung cancer (NSCLC)Germany · Hungary · Italy